Moderna CEO Bancel offers a thumbs-up on latest update for their CMV program — with blockbuster hopes for what's ahead
Moderna is rolling out a positive update to their proof-of-concept study for their mRNA program for a CMV vaccine — and CEO Stéphane Bancel is happy to discuss what he sees as a potential company-building blockbuster in the making.
Following a third vaccination researchers tracked an increasing level of neutralizing antibody titers, which is exactly what they wanted to see.
They $MRNA report:
Neutralizing antibody titers against epithelial cell infection were greater than 10-fold higher than CMV-seropositive baseline titers at the 90 and 180 μg dose levels after the third vaccine, compared to 3-fold to 5-fold higher after the second vaccination.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,500+ biopharma pros reading Endpoints daily — and it's free.